Men’s mutant population possesses some mutant abilities so inconceivably powerful that they must be distinguished from the ...

Genetic information collected through research studies like Geisinger's MyCode Community Health Initiative can provide ...

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

Bank of New York Mellon Corp lowered its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 13.5% in the ...

The Federated European Genome–Phenome Archive as a global network for sharing human genomics data, Nature Genetics (2025). DOI: 10.1038/s41588-025-02101-9 ...

Shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Free Report) have received a consensus rating of “Hold” from the seventeen analysts that are currently covering the company, Ratings reports. One ...

Mammalian genomes are organized by multi-level folding, yet how this organization contributes to cell type-specific transcription remain unclear. We uncovered that the nuclear protein SATB1 ...

Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT ... Plate-based workflows for Chromium GEM-X Flex: The company announced plans for plate-based GEM-X Flex ...

Whitaker, Chief Legal Officer of 10x Genomics. "We are pleased with this resolution on ATAC as we continue to defend the asserted Brenner patents on appeal." The company's litigation against Parse ...

PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.